Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alphacait Screening for Advanced Solid Tumors
NCT03299452Phase 2Unknown
- Sponsor
- Haining Health-coming Biotech
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in solid tumor, sponsored by Haining Health-coming Biotech. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03299452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299452.